Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Philippines FDA/Myozyme

Approved

STANDARD

Myozyme

Genzyme Ireland Limited🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 7f0872cc9904ff5e
Company: Genzyme Ireland Limited
Type: Standard

Approval Details

Approval Id: 7f0872cc9904ff5e
Drug Approval Philippines Name: Myozyme
Product Name: Myozyme
Registration Number: BR-893
Brand Name: Myozyme
Generic Name: Alglucosidase alfa
Dosage Form: Powder For Concentrate For Solutions For Infusion (IV)
Dosage Strength: 50 mg
Manufacturer: Genzyme Ireland Limited
Importer: Sanofi-Aventis Philippines, Inc.
Distributor: Sanofi-Aventis Philippines, Inc.
Company Detail Path: /organization/genzyme-ireland-limited
Issuance Date: 26 April 2023
Expiry Date: 31 January 2028
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

7f0872cc9904ff5e

Type

Standard

Back to Philippines FDA Approvals

Myozyme - Philippines FDA Drug Approval Details